Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ischemic Heart Disease

Free Subscription Articles published in Am Heart J Retrieve available abstracts of 116 articles: HTML format

Single Articles

October 2025
1. LEOSDOTTIR M, Dahlbom L, Back M, Wallentin L, et al
   Data quality assessment in the SWEDEHEART registry: Insights from serial audits on completeness and accuracy.
   Am Heart J. 2025;288:149-158.
   PubMed     Abstract available
   
   
   September 2025
2. FEISTRITZER HJ, Jobs A, Zeymer U, Schneider S, et al
   Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease - Design and rationale of the randomized COMPLETE-NSTEMI trial.
   Am Heart J. 2025;287:94-106.
   PubMed     Abstract available
   
   
   August 2025
3. SARMA D, Smith R, Padkins M, Rali AS, et al
   Association between vasopressin administration and mortality in patients with cardiogenic shock.
   Am Heart J. 2025;286:88-96.
   PubMed     Abstract available
   
   
   
4. DANDAMUDI K, Lawson BD, Barrett JC, Trankle CR, et al
   Trends of women in cardiovascular disease fellowships 2013-2022.
   Am Heart J. 2025;286:111-115.
   PubMed     Abstract available
   
   
   July 2025
5. KHAN E, Lambrakis K, Briffa T, Cullen LA, et al
   Re-engineering the clinical approach to suspected cardiac chest pain assessment in the emergency department by expediting research evidence to practice using artificial intelligence. (RAPIDx AI)-a cluster randomized study design.
   Am Heart J. 2025;285:106-118.
   PubMed     Abstract available
   
   
   
6. DURAN AT, Barbecho JM, Shaw K, Ye S, et al
   Implementing depression treatment for cardiac populations in rapidly changing contexts: Design of the hybrid effectiveness-implementation IHEART DEPCARE trial.
   Am Heart J. 2025;285:52-65.
   PubMed     Abstract available
   
   
   June 2025
7. CUTLIP DE, Mehran R, Doros G, Kaplinskiy V, et al
   Prospective randomized single-blind multicenter study to assess the safety and effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of subjects with in-stent restenosis: Rationale and design.
   Am Heart J. 2025;284:11-19.
   PubMed     Abstract available
   
   
   May 2025
8. GENG Q, Ying Z, Zhenyan M, Renqiang Y, et al
   Long-term Prognostic Role of Persistent Microvascular Obstruction Determined by Cardiac Magnetic Resonance for ST-segment Elevation Myocardial Infarction.
   Am Heart J. 2025 May 29:S0002-8703(25)00187-5. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
9. MAINI AS, Abu-Much A, Redfors B, Wollmuth JR, et al
   Outcomes Among Patients with Coronary Bifurcation Lesions Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention.
   Am Heart J. 2025 May 22:S0002-8703(25)00176-0. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
10. WHITE HD, O'Brien SM, Boden WE, Fremes SE, et al
    Use of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Intervention and Associated Outcomes in the ISCHEMIA Trial.
    Am Heart J. 2025 May 20:S0002-8703(25)00165-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
11. GOLD ME, Kulkarni S, Yadalam A, Patel KJ, et al
    Cardiac Allograft Vasculopathy Mediates the Relationship Between Vitamin D Deficiency and Cardiovascular Mortality Following Heart Transplantation.
    Am Heart J. 2025 May 16:S0002-8703(25)00166-8. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
12. RAI B, Yildiz M, Bergstedt S, Bandari A, et al
    Diversity of Electrocardiographic Patterns in Left Main Culprit Acute ST-Elevation Myocardial Infarction.
    Am Heart J. 2025 May 14:S0002-8703(25)00164-4. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
13. MESSINGER MC, Ashburn NP, Chait JS, Snavely AC, et al
    Risk of delayed percutaneous coronary intervention for STEMI in the Southeast United States.
    Am Heart J. 2025 May 13:S0002-8703(25)00157-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
14. CARULLI E, McGarvey M, Chabok M, Panoulas V, et al
    Corrigendum to ;;Transcoronary cooling and dilution for cardioprotection during revascularisation for ST-segment elevation myocardial infarction: design and rationale of the STEMI-Cool study''. [Am Heart J. 2025:282:40-50].
    Am Heart J. 2025;288:89.
    PubMed    
    
    
    
15. JAMES S, Christoffersen AD, David JP, Hacker M, et al
    Effect of Once-Weekly Subcutaneous Semaglutide on Arterial Inflammation in People with Type 2 Diabetes and Cardiovascular Disease Using PET-MRI: Primary Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Am Heart J. 2025 May 7:S0002-8703(25)00156-5. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
16. KANDZARI DE, Latib A, Mylotte D, Ali ZA, et al
    Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease.
    Am Heart J. 2025;283:26-36.
    PubMed     Abstract available
    
    
    April 2025
17. BERGER JS, Lyu C, Iturrate E, Westerhoff M, et al
    Opportunistic Assessment of Abdominal Aortic Calcification using Artificial Intelligence (AI) Predicts Coronary Artery Disease and Cardiovascular Events.
    Am Heart J. 2025 Apr 24:S0002-8703(25)00137-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
18. SOH CH, Chen J, Marwick TH
    Incidence Rate of Coronary Atherosclerosis among Cancer Types during Survivorship: A Systematic Review and Meta-Analysis.
    Am Heart J. 2025 Apr 23:S0002-8703(25)00142-5. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
19. CROOIJMANS C, Jansen T, van de Hoef TP, Paradies V, et al
    Design and rationale of the efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled trial (EDIT-CAS).
    Am Heart J. 2025 Apr 22:S0002-8703(25)00138-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
20. DILLINGER JG, Pezel T, Batias L, Angoulvant D, et al
    Twice-a-day administration of aspirin in patients with diabetes mellitus or aspirin resistance after acute coronary syndrome: Rationale and design of the randomized ANDAMAN trial.
    Am Heart J. 2025 Apr 21:S0002-8703(25)00132-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
21. LI L, Sun H, Jin Z, Li J, et al
    Positive outcome trials driven by reduction in nonfatal myocardial infarction: A systematic review and relevant guideline recommendations.
    Am Heart J. 2025 Apr 18:S0002-8703(25)00136-X. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
22. HAKEEM A, Ali Shah J, Kumar R, Khan K, et al
    Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a Day Clopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary Intervention.
    Am Heart J. 2025 Apr 12:S0002-8703(25)00103-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
23. NATHAN A
    Response to letter by Ferguson regarding article, "Revenues, costs, and contribution margins of major inpatient cardiovascular procedures within the Medicare population.".
    Am Heart J. 2025 Apr 10:S0002-8703(25)00126-7. doi: 10.1016/j.ahj.2025.
    PubMed    
    
    
    
24. FERGUSON M
    Letter by Ferguson regarding article, "Revenues, costs, and contribution margins of major inpatient cardiovascular procedures within the Medicare population.".
    Am Heart J. 2025 Apr 9:S0002-8703(25)00125-5. doi: 10.1016/j.ahj.2025.
    PubMed    
    
    
    
25. SOMSEN YBO, de Winter RW, Wu J, Hoek R, et al
    Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial.
    Am Heart J. 2025 Apr 7:S0002-8703(25)00105-X. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
26. KULASINGAM A, Laustsen S, Busk M, Sand NP, et al
    Rationale and Design of VICAD-RISK study: Visualization of Coronary Artery Disease for Modification of Risk Factors.
    Am Heart J. 2025 Apr 3:S0002-8703(25)00107-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
27. PINCOMBE A, Gray J, Hickling S, Sanfilippo F, et al
    Cost-effectiveness of the transition from Conventional to High-Sensitivity Troponin Assay for the Investigation and Management of Suspected Acute Coronary Syndrome in the Emergency Department.
    Am Heart J. 2025 Apr 2:S0002-8703(25)00104-8. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
28. CHO L, Nicholls SJ, Nordestgaard BG, Landmesser U, et al
    Design and rationale of Lp(a)HORIZON trial: Assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a).
    Am Heart J. 2025 Apr 2:S0002-8703(25)00101-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    March 2025
29. HOFMANN R, James S, Sundqvist MO, Warme J, et al
    HELicobacter Pylori screening to prevent gastrointestinal bleeding in patients with acute Myocardial Infarction(HELP-MI SWEDEHEART)Design and rationale of a cluster randomized, crossover, registry-based clinical trial.
    Am Heart J. 2025 Mar 27:S0002-8703(25)00096-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
30. NOORY N, Westin O, Borgersen EH, Kragelund C, et al
    Absence of Coronary Artery Disease in Patients Undergoing Coronary Imaging and Association with Amyloidosis - A Danish Nationwide Study.
    Am Heart J. 2025 Mar 26:S0002-8703(25)00093-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
31. ZEYMER U, Hassinger F, Bramlage P, Schafer A, et al
    Hyperoxemic Oxygen Therapy in Patients with Acute Anterior Myocardial Infarction: HOT-AAMI - Design and Rationale of a Randomized Trial.
    Am Heart J. 2025 Mar 21:S0002-8703(25)00095-X. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
32. OSUDE N, Spall HV, Bosworth H, Krychtiuk K, et al
    Advancement of the Implementation of Evidence-based Therapies for Cardiovascular-Kidney-Metabolic Conditions: A Multi-Stakeholder Perspective.
    Am Heart J. 2025 Mar 17:S0002-8703(25)00084-5. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
33. ONUMA Y, Ninomiya K, Sjauw K, Damman P, et al
    Accuracy of Instantaneous Wave-free Ratio and Fractional Flow Reserve Derived From Single Coronary Angiographic Projections.
    Am Heart J. 2025 Mar 11:S0002-8703(25)00071-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
34. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Olezarsen in Patients with Hypertriglyceridemia at High Cardiovascular Risk: Rationale and Design of the Essence-TIMI 73b Trial.
    Am Heart J. 2025 Mar 11:S0002-8703(25)00072-9. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
35. YU J, Indraratna P, Briggs NE, Brown P, et al
    Rationale and design of the TeleClinical Care (TCC) -Cardiac trial: A pragmatic randomized trial of adjunctive virtual models of care in the secondary prevention of cardiovascular events.
    Am Heart J. 2025 Mar 11:S0002-8703(25)00091-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
36. SERPA F, Perera S, Cruz D, Figueroa JF, et al
    Cardiovascular Health, Lifestyle Factors, and Social Determinants Among Hispanic or Latino Adults in the United States.
    Am Heart J. 2025 Mar 9:S0002-8703(25)00070-5. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
37. LAI Y, Zhang S, Guo Y, Xu C, et al
    Apolipoprotein B modifies the association between lipoprotein(a) and ASCVD risk.
    Am Heart J. 2025;281:157-167.
    PubMed     Abstract available
    
    
    
38. PATEL S, Fung M, Prasai S, Butalia S, et al
    Emergency department visits and hospitalizations after a diagnosis of angina with no obstructive coronary artery disease (ANOCA).
    Am Heart J. 2025 Mar 1:S0002-8703(25)00067-5. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    February 2025
39. AUER J, Lamm G
    High-risk features and probability of ischemic and bleeding events after percutaneous coronary intervention.
    Am Heart J. 2025 Feb 26:S0002-8703(25)00058-4. doi: 10.1016/j.ahj.2025.
    PubMed    
    
    
    
40. JACOBSEN MR, Jabbari R, Grove EL, Maeng M, et al
    Genotype-guided de-escalation and abbreviation of dual antiplatelet therapy in patients with myocardial infarction and high bleeding risk: Design and rationale of the investigator-initiated, multicenter, randomized, controlled trial, DAN-DAPT.
    Am Heart J. 2025 Feb 25:S0002-8703(25)00059-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
41. TAKAHASHI T, Wei J, Iribarren AC, Gulati M, et al
    Rationale and design of the Women's Ischemia Syndrome Evaluation Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure With Preserved Ejection Fraction (WISE Pre-HFpEF).
    Am Heart J. 2025 Feb 24:S0002-8703(25)00056-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
42. HAFF N, Horn DM, Bhatkhande G, Sung M, et al
    Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial.
    Am Heart J. 2025 Feb 20:S0002-8703(25)00038-9. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
43. GIBSON CM, Bahit MC, Mehran R, Mehta SR, et al
    Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS).
    Am Heart J. 2025 Feb 20:S0002-8703(25)00044-4. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
44. ERRIQUEZ A, Colaiori I, Hakeem A, Guiducci V, et al
    Functional Coronary Angiography to Indicate and Guide Revascularization in STEMI Patients with Multivessel Disease: Rationale and Design of the AIR-STEMI trial: Functional coronary angiography in STEMI patients.
    Am Heart J. 2025 Feb 19:S0002-8703(25)00042-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
45. LEENING MJG, Khan CF, Zhu F, Singh SS, et al
    Lipoprotein(a) immunoassays and their associations with coronary artery calcification and aortic valve calcification.
    Am Heart J. 2025 Feb 18:S0002-8703(25)00040-7. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
46. TIAN Y, Wang X, Hu Z, Yu X, et al
    Design, rationale, and characterization of the Mobile health based OccuPational cardiovascular risk intErventioN study (mHealth-OPEN Study).
    Am Heart J. 2025 Feb 13:S0002-8703(25)00035-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
47. BAINEY KR, Welsh RC, Zheng Y, Arias-Mendoza A, et al
    Pharmaco-invasive Strategy and Dosing of Tenecteplase in STEMI Patients 60 to <75 Years: An Inter-trial Comparison of the STREAM-1 and STREAM-2 Trials: Comparison of Patients 60 to <75 Years in STREAM-1 and -2.
    Am Heart J. 2025 Feb 12:S0002-8703(25)00032-8. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
48. GAO XF, Kan J, Wu HY, Chen J, et al
    Intravascular Imaging-guided versus Angiography-guided Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: Rationale and design of an International, Multicenter, Randomized IVI-DIABETES Trial.
    Am Heart J. 2025 Feb 4:S0002-8703(25)00017-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
49. WANG G, Zhang R, Chen SL, Wang J, et al
    Targeted Therapy with a Localized abluminal Groove Low-Dose Sirolimus-Eluting Bioabsorbable Polymer Coronary Stent in Chronic Total Occlusions: The TARGET CTO Non-Inferiority Randomized Trial.
    Am Heart J. 2025 Feb 3:S0002-8703(25)00018-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
50. MACHLINE-CARRION MJ, Girotto AN, Raupp P, Marton Pereira P, et al
    Rationale, design and pre-randomization data for a cluster randomized trial to assess the effect of a digitally enabled quality improvement intervention on LDL-C control in established atherosclerotic cardiovascular disease patients: The SAPPHIRE-LDL
    Am Heart J. 2025 Feb 3:S0002-8703(25)00020-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    January 2025
51. STEG PG, Nicolas J, Baber U, Sartori S, et al
    Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial.
    Am Heart J. 2025 Jan 29:S0002-8703(25)00016-X. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
52. EFTEKHARI A, Christiansen EH, Lassen JF, Raungaard B, et al
    Randomized comparison of the combined Sirolimus eluting and endothelial progenitor cell Combo(TM) stent vs. Biolimus eluting absorbable polymer coated BioMatrix Alpha(TM) stent in patients undergoing percutaneous coronary intervention. Rationale and s
    Am Heart J. 2025 Jan 25:S0002-8703(25)00013-4. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
53. EBRAHIMI M, Fonarow GC
    Higher Levels of Glucose within the Normal Range and Cardiovascular Risk: A Landscape Beyond Diabetes and Prediabetes.
    Am Heart J. 2025 Jan 23:S0002-8703(25)00008-0. doi: 10.1016/j.ahj.2025.
    PubMed    
    
    
    
54. PORTELA GT, Ducrocq G, Bertolet M, Alexander JH, et al
    Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia.
    Am Heart J. 2025 Jan 16:S0002-8703(25)00009-2. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
55. POLOMSKI EAS, Heemelaar JC, de Ronde MES, Al Jaff AAM, et al
    Increased Prevalence of Coronary Atherosclerosis in Cancer Survivors: A Retrospective Matched Cross-sectional Study with Coronary CT Angiography.
    Am Heart J. 2025 Jan 8:S0002-8703(25)00004-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
56. BRIX GS, Rasmussen LD, Rohde PD, Nissen L, et al
    Elevated lipoprotein(a) is independently associated with the presence of significant coronary stenosis in de-novo patients with stable chest pain.
    Am Heart J. 2025 Jan 7:S0002-8703(25)00001-8. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
57. VAN STEENWIJK MPJ, van Rosmalen J, Elzo Kraemer CV, Donker DW, et al
    A randomized embedded multifactorial adaptive platform for extra corporeal membrane oxygenation (REMAP ECMO) - design and rationale of the left ventricular unloading trial domain.
    Am Heart J. 2025;279:81-93.
    PubMed     Abstract available
    
    
    December 2024
58. CARULLI E, McGarvey M, Chabok M, Panoulas V, et al
    Transcoronary cooling and dilution for cardioprotection during revascularisation for ST-segment elevation myocardial infarction: design and rationale of the STEMI-Cool study.
    Am Heart J. 2024 Dec 30:S0002-8703(24)00338-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
59. BURGESS S, Zaman S, Towns C, Coylewright M, et al
    The under-representation of women in cardiovascular clinical trials: State-of-the-art review and ethical considerations.
    Am Heart J. 2024 Dec 27:S0002-8703(24)00340-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
60. NELSON AJ, Kaltenbach LA, McGuire DK, Levya M, et al
    Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.
    Am Heart J. 2024 Dec 21:S0002-8703(24)00336-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
61. XU L, Xu H, Wu S, Zhang H, et al
    Indobufen-based Dual Antiplatelet Therapy in Patients with Multivessel Coronary Disease Undergoing Drug-eluting Stent Implantation Insight From the OPTION Trial.
    Am Heart J. 2024 Dec 20:S0002-8703(24)00335-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
62. CASSESE S, Simonetti F, Covarrubias HAA, Janisch M, et al
    Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy: Design and Rationale of ISAR-WAVE Trial.
    Am Heart J. 2024 Dec 20:S0002-8703(24)00337-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
63. POLLACK LM, Chang A, Thompson MP, Keteyian SJ, et al
    Hospital-level variation in cardiac rehabilitation metrics.
    Am Heart J. 2024 Dec 13:S0002-8703(24)00333-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
64. KAUL P, Barrett O, Savu A, Liyanage V, et al
    Association between adverse birth outcomes and long-term risk of premature cardiovascular disease and mortality in a contemporary population-based cohort of 502,383 pregnant women.
    Am Heart J. 2024 Dec 12:S0002-8703(24)00331-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
65. AARTS HM, Hemelrijk KI, Broeze GM, van Ginkel DJ, et al
    Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: rationale and design of the PRO-TAVI trial: the PRO-TAVI trial: rationale and design.
    Am Heart J. 2024 Dec 12:S0002-8703(24)00332-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
66. IKEMURA N, Chan PS, Gosch K, Nguyen DD, et al
    Health Status Outcomes after Acute Myocardial Infarction in Patients without Standard Modifiable Risk Factors.
    Am Heart J. 2024 Dec 3:S0002-8703(24)00317-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
67. REDDY KP, Shutlz K, Eberly LA, Khatana SAM, et al
    Revenues, costs, and contribution margins of major inpatient cardiovascular procedures within the Medicare population.
    Am Heart J. 2024 Dec 2:S0002-8703(24)00305-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
68. BUDGEON CA, Nidorf S, Mosterd A, Fiolet A, et al
    Exploration of the regional effects of colchicine in the LoDoCo2 trial.
    Am Heart J. 2024;278:186-194.
    PubMed     Abstract available
    
    
    
69. KHAND A, Hatherley J, Dakshi A, Miller G, et al
    Safety and feasibility of triage and rapid discharge of patients with chest pain from emergency room: A pragmatic, randomized noninferiority control trial of the European Society of Cardiology (ESC) 0 to 1 hour pathway vs conventional 0 to 3 hour acce
    Am Heart J. 2024;278:235-247.
    PubMed     Abstract available
    
    
    November 2024
70. ARAIZA-GARAYGORDOBIL D, Gopar-Nieto R, Sierra-Lara Martinez JD, S Ajit M, et al
    A randomized trial of antithrombotic therapy in patients with acute coronary syndrome and coronary ectasia.
    Am Heart J. 2024 Nov 28:S0002-8703(24)00304-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
71. FANAROFF AC, Vora AN, Wojdyla DM, Mehran R, et al
    Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS.
    Am Heart J. 2024 Nov 16:S0002-8703(24)00297-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
72. ENGEL-REBITZER E, Marinacci L, Zheng Z, Wadhera RK, et al
    Changes in coverage, access, and health status among adults with cardiovascular disease after medicaid work requirements.
    Am Heart J. 2024 Nov 14:S0002-8703(24)00276-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
73. NOORY N, Westin O, Maurer MS, Fosbol E, et al
    Chest pain and coronary artery disease in cardiac amyloidosis: Prevalence, mechanisms, and clinical implications.
    Am Heart J. 2024 Nov 14:S0002-8703(24)00296-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
74. ERLINGE D, Andersson J, Frobert O, Tornerud M, et al
    Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent.
    Am Heart J. 2024;277:1-10.
    PubMed     Abstract available
    
    
    
75. NAVAS-ACIEN A, Mark DB, Anstrom K, Lamas GA, et al
    Response to Tomoyuki Kawada: Blood and urine metal levels in patients with diabetes and cardiovascular disease.
    Am Heart J. 2024;277:143-144.
    PubMed    
    
    
    
76. KAWADA T
    Blood and urine metal levels in patients with diabetes and cardiovascular disease.
    Am Heart J. 2024;277:142.
    PubMed    
    
    
    October 2024
77. BARONE-ROCHETTE G, Vanzetto G, Danchin N, Steg PG, et al
    Rationale and design of the multicentric randomized EVAOLD trial: evaluation of a strategy guided by imaging versus routine invasive strategy in elderly patients with ischemia.
    Am Heart J. 2024 Oct 22:S0002-8703(24)00274-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
78. SHAH NP, Mulder H, Lydon B, Chiswell K, et al
    Real-World Exploration of LDL-Cholesterol Management in Patients with Atherosclerotic Cardiovascular Disease.
    Am Heart J. 2024 Oct 16:S0002-8703(24)00271-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
79. LUSK JB, Glover L, Soneji S, Granger CB, et al
    Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.
    Am Heart J. 2024;276:110-114.
    PubMed     Abstract available
    
    
    September 2024
80. VOLPP KG, Mahraj K, Norton LA, Asch DA, et al
    Design and Rationale of Penn Medicine Healthy Heart, a Randomized Trial of Effectiveness of a Centrally Organized Approach to Blood Pressure and Cholesterol Improvement Among Patients at Elevated Risk of Atherosclerotic Cardiovascular Disease.
    Am Heart J. 2024 Sep 26:S0002-8703(24)00262-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
81. KODAIRA M, Hasan MS, Grossman Y, Guerrero C, et al
    Risk of Cardiovascular Events after Influenza Infection-related Hospitalizations in Adults with Congenital Heart Disease -A Nationwide Population Based Study.
    Am Heart J. 2024 Sep 4:S0002-8703(24)00226-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
82. NELSON MD, Gomez-Arnold JM, Wei J, Lauzon M, et al
    Contributors to high left ventricular ejection fraction in women with ischemia and no obstructive coronary artery disease: Results from the Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction (WISE-CVD) Study.
    Am Heart J. 2024 Sep 2:S0002-8703(24)00224-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
83. DE COCK E, Kautbally S, Timmermans F, Bogaerts K, et al
    Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: rationale and design of the COL BE PCI trial: Short title: Rationale and design of the COL BE PCI trial.
    Am Heart J. 2024 Sep 2:S0002-8703(24)00225-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    August 2024
84. HAMID H, Bagheri M, Benzing T, Krishnan S, et al
    Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the Tirzepatide treatment on coronary atherosclerosis progression: The (T-PLAQUE) randomized-controlled trial design: tirzepatide and plaque.
    Am Heart J. 2024 Aug 24:S0002-8703(24)00218-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
85. JIANG C, Wang Z, Du X, Wang Y, et al
    Protocol for a randomized controlled trial of intensive blood pressure control on cardiovascular risk reduction in patients with atrial fibrillation: rationale and design of the CRAFT trial.
    Am Heart J. 2024 Aug 23:S0002-8703(24)00203-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
86. BROWN TM
    Cholesterol Lowering Therapy is Highly Efficacious in Reducing Atherosclerotic Cardiovascular Disease Risk but Grossly Underutilized: How do we Move the Needle?
    Am Heart J. 2024 Aug 16:S0002-8703(24)00201-1. doi: 10.1016/j.ahj.2024.
    PubMed    
    
    
    
87. DISMORR M, Granbom-Koski M, Ellfors E, Ruck A, et al
    Sex differences and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Aug 9:S0002-8703(24)00185-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
88. AIHARA K, Torii S, Nakamura N, Hozumi H, et al
    Pathological Evaluation of Predictors for Delayed Endothelial Coverage After Currently Available Drug-eluting Stent Implantation in Coronary Arteries: Impact of Lesions With Acute and Chronic Coronary Syndromes.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00197-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
89. STAHLI BE, Linke A, Westermann D, Van Mieghem NM, et al
    A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of the TAVI PCI Trial.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00184-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
90. VOGEL B, Jou S, Sartori S, Farhan S, et al
    Impact of sex on outcomes associated with polyvascular disease in patients after PCI.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00196-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    July 2024
91. ERBAY A, Penzel L, Abdelwahed YS, Heuberger A, et al
    Prognostic impact of quantitative flow ratio (QFR)-consistent complete revascularization in patients with myocardial infarction and multivessel coronary artery disease.
    Am Heart J. 2024 Jul 19:S0002-8703(24)00177-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
92. SINGH K, Nikhare K, Gandral M, Aithal K, et al
    Rationale, Design and Baseline Characteristics of a Randomized Controlled Trial of a Cardiovascular Quality Improvement Strategy in India: The C-QIP Trial.
    Am Heart J. 2024 Jul 19:S0002-8703(24)00174-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
93. VERGHESE D, Hamal S, Ghanem A, Kinninger A, et al
    Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients with STable CoROnary Artery Disease CoMpared to Placebo (EKSTROM) Trial - Rationale and Design.
    Am Heart J. 2024 Jul 17:S0002-8703(24)00171-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    June 2024
94. JEYAPRAKASH P, Pathan F, Ozawa K, Robledo KP, et al
    Restoring microvascular circulation with diagnostic ultrasound and contrast agent: Rationale and Design of the REDUCE trial.
    Am Heart J. 2024 Jun 27:S0002-8703(24)00162-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
95. WU ZM, Kan J, Ye F, You W, et al
    PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study.
    Am Heart J. 2024 Jun 26:S0002-8703(24)00157-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
96. D'ENTREMONT MA, Lee SF, Mian R, Kedev S, et al
    Design and Rationale of the CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction.
    Am Heart J. 2024 Jun 25:S0002-8703(24)00161-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
97. RAMASESHAN R, Perera D, Reid A, Andiapen M, et al
    REGENERATE-COBRA: A Phase II randomized sham-controlled trial assessing the safety and efficacy of intracoronary administration of autologous bone marrow-derived cells in patients with refractory angina.
    Am Heart J. 2024 Jun 9:S0002-8703(24)00146-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
98. SONG L, Guan C, Yu M, Sun Z, et al
    Sirolimus-eluting iron bioresorbable scaffold versus cobalt-chromium everolimus-eluting stents in patients with coronary artery disease: rationale and design of the IRONMAN-II trial.
    Am Heart J. 2024 Jun 3:S0002-8703(24)00140-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    May 2024
99. MOK Y, Lu Y, Ballew SH, Sang Y, et al
    Premorbid physical activity and prognosis after incident myocardial infarction: the Atherosclerosis Risk in Communities Study.
    Am Heart J. 2024 May 7:S0002-8703(24)00120-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
100. KIM Y, Park H, Yoon HJ, Suh J, et al
     Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH): Study Protocol for a Randomized Controlled Non-Inferiority Trial.
     Am Heart J. 2024 May 7:S0002-8703(24)00119-4. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
101. ZHANG F, Tian M, Wang X, Zhang H, et al
     Rationale and design of a Single-center Randomized Trial to Compare the Graft Patency between the Radial Artery and the No-touch Saphenous Vein in Coronary Artery Bypass Grafting Surgery (GRAFT-CAB Study).
     Am Heart J. 2024 May 4:S0002-8703(24)00117-0. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
102. NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al
     Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN.
     Am Heart J. 2024 May 3:S0002-8703(24)00116-9. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
103. COOPER JG, Ferguson J, Donaldson LA, Black KMM, et al
     Could paramedics use the HEART Pathway to identify patients at low-risk of myocardial infarction in the prehospital setting?
     Am Heart J. 2024;271:182-187.
     PubMed     Abstract available
     
     
     April 2024
104. SAPP JL, Tang ASL, Parkash R, Stevenson WG, et al
     A Randomized Clinical Trial of Catheter Ablation and Antiarrhythmic Drug Therapy for Suppression of Ventricular Tachycardia in Ischemic Cardiomyopathy: The VANISH2 Trial.
     Am Heart J. 2024 Apr 20:S0002-8703(24)00096-6. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
105. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
     Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial.
     Am Heart J. 2024 Apr 17:S0002-8703(24)00078-4. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
106. DAUBERT MA, Stebbins A, Peragallo-Urrutia R, Chiswell K, et al
     Early Postpartum Blood Pressure Screening is Associated with Increased Detection of Cardiovascular Risk Factors in Women with Hypertensive Disorders of Pregnancy.
     Am Heart J. 2024 Apr 4:S0002-8703(24)00076-0. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
107. PARK DY, Jamil Y, Babapour G, Kim J, et al
     Association of Cardiovascular Diseases with Cognitive Performance in Older Adults.
     Am Heart J. 2024 Apr 2:S0002-8703(24)00077-2. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     March 2024
108. THOMAS A, Banna S, Shahu A, Ali T, et al
     Propofol vs etomidate for induction prior to invasive mechanical ventilation in patients with acute myocardial infarction.
     Am Heart J. 2024 Mar 28:S0002-8703(24)00074-7. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
109. WU Y, Hu L, Xie X, Li W, et al
     Different Dose Aspirin Plus Immunoglobulin (DAPI) for Prevention of Coronary Artery Abnormalities in Kawasaki Disease: Study Protocol for a Multi-centre, Prospective, Randomized, Open-label, Blinded End-point, Non-inferiority Trial.
     Am Heart J. 2024 Mar 18:S0002-8703(24)00071-1. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
110. KRUCOFF M, Spirito A, Baber U, Sartori S, et al
     Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients With Concomitant Peripheral Artery Disease: a subgroup analysis of the TWILIGHT randomized clinical trial.
     Am Heart J. 2024 Mar 6:S0002-8703(24)00053-X. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     February 2024
111. MEHDIPOOR G, Redfors B, Chen S, Gkargkoulas F, et al
     Hypertension, Microvascular Obstruction and Infarct Size in Patients with STEMI Undergoing PCI: Pooled Analysis from 7 Cardiac Magnetic Resonance Imaging Studies.
     Am Heart J. 2024 Feb 29:S0002-8703(24)00050-4. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
112. ZIEGELSTEIN RC, Kronish IM, Thombs BD
     Depression Screening to Improve Clinical Outcomes in Coronary Heart Disease Patients.
     Am Heart J. 2024 Feb 22:S0002-8703(24)00044-9. doi: 10.1016/j.ahj.2024.
     PubMed    
     
     
     
113. LEE SH, Lee SJ, Heo JH, Ahn SG, et al
     Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial.
     Am Heart J. 2024 Feb 22:S0002-8703(24)00041-3. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     
114. DEHGHANI P, Singh J, Mancini GBJ, Stanberry L, et al
     Angiographic characteristics of Patients with STEMI and COVID-19 - Insights from NACMI Registry.
     Am Heart J. 2024 Feb 21:S0002-8703(24)00039-5. doi: 10.1016/j.ahj.2024.
     PubMed     Abstract available
     
     
     January 2024
115. ALVIAR CL, Li BK, Keller NM, Bohula-May E, et al
     Prognostic Performance of the IABP-SHOCK II Risk Score Among Cardiogenic Shock Subtypes in the Critical Care Cardiology Trials Network Registry.
     Am Heart J. 2024 Jan 6:S0002-8703(23)00361-7. doi: 10.1016/j.ahj.2023.
     PubMed     Abstract available
     
     
     November 2023
116. MUNHOZ D, Collet C, Mizukami T, Yong A, et al
     Rationale and design of the pullback pressure gradient (PPG) global registry.
     Am Heart J. 2023;265:170-179.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge.